Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Crypto platform Gemini files for Nasdaq IPO

(Sharecast News) - New York-based crypto platform Gemini said on Tuesday that it was seeking a valuation of up to $2.2bn in a US initial public offering. The company, which was founded by Cameron and Tyler Winklevoss in 2014, offers a wide range of crypto products and services for individuals and institutions in over 60 countries.

Gemini said it plans to sell just over 16.6m shares at between $17 and $19 each.

Goldman Sachs, Citigroup, Morgan Stanley and Cantor are acting as lead bookrunners and Gemini said it plans to list on the Nasdaq under the ticker symbol 'GEMI'.

Jacob Zuller, analyst at Third Bridge, said: "Gemini has chosen the perfect time to capitalise on the favourable environment, following the recent success of the Bullish IPO and regulatory shifts from a pro-crypto administration. For Gemini, the IPO is both a bid to raise capital for expansion and an effort to clean up its balance sheet.

"Klarna reported a net loss of $282.5 million in H1 2025, a substantial increase from the $41.4 million loss in the same period in 2024. The struggles stem from declining trading volumes, while competition in credit cards - an area where Gemini had a competitive advantage - is heating up. Third Bridge experts highlight that trading volumes are expected to increase, driven by institutional adoption, which represents the majority of Gemini's client base, but the company could face challenges in attracting net new accounts due to reputational concerns from the Gemini Earn situation.

"Investors will be watching the company's growth story to judge its valuation, whether it focuses on Europe with tokenized stocks and its MiCA license, or a bigger push in marketing in the US."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.